multiple sclerosis and glp 1 A Phase 2 trial just began testing whether a GLP-1 drug can slow brain shrinkage Repurposing glucagon-like peptide-1 receptor agonists

Scott Gottlieb, the FDAs former commissioner, said on CNBC that many of the compounds wont deliver the expected benefit. The agencys safety concerns appear to be well founded: between February 2019 and December 2023, the FDA received 352 adverse event reports related to compounded GLP-1 drugs, including five deaths

If inflammation in the brain could be reversed, this could be especially helpful in neurodegenerative diseases

The most successful long-term outcomes usually involve nutrition, muscle protection, movement, behaviour change, emotional support and realistic expectations

For someone taking Ozempic, which works partly by suppressing appetite and promoting satiety, cannabis-induced hunger could potentially counteract the medication's appetite-suppressing effects